Skip to main content

PLN-74809-ARDS-204 A randomized, double-blind, dose-ranging, placebo controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with acute respiratory distress syndrome (ARDS) associated with at least se

A randomized, double-blind, dose-ranging, placebo controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with acute respiratory distress syndrome (ARDS) associated with at least severe COVID-19

Associated Conditions

COVID-19

Principal Investigator

Sponsor

Pilant Therapeautics

This research study is studying an investigational drug, PLN-74809 (“study drug”), as a possible treatment in participants with acute respiratory distress syndrome (ARDS) associated with at least severe COVID-19 as there are limited available treatment options outside of the research study setting. You are being asked to participate in the study because you have been hospitalized, diagnosed with COVID-19, and have a clinical diagnosis of ARDS. Pliant Therapeutics is sponsoring (paying for) this research study.

This study is currently enrolling.